Dries Heylen

Mr. Dries Heylen


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
DHDries Heylen
Dries Heylen
MPMurih Pusparum
Murih Pusparum
JKJurgis Kuliesius
Jurgis Kuliesius
JWJim Wilson
Jim Wilson
YPYoung-Chan Park
Young-Chan Park
JHJef Hooyberghs
Jef Hooyberghs
Proteomics stands as the crucial link between genomics and human diseases. Quantitative proteomics provides detailed insights into protein levels, enabling differentiation between distinct phenotypes. OLINK, a biotechnology company from Uppsala, Sweden, offers a targeted, affinity-based protein measurement method called Target 96, which has become prominent in the field of proteomics. The SCALLOP consortium, for instance, contains data from over 70.000 individuals across 45 independent cohort studies, all sampled by OLINK. However, when independent cohorts want to collaborate and quantitatively compare their target 96 protein values, it is currently advised to include 'identical biological bridging' samples in each sampling run to perform a reference sample normalization, correcting technical variations across measurements. Such a ‘biological bridging sample’ approach requires each of the involved cohorts to resend their biological bridging samples to OLINK to run them all together, which is logistically challenging, costly and time-consuming. Hence alternatives are searched and an evaluation of the current state of the art exposes the need for a more robust method that allows all OLINK Target 96 studies to compare proteomics data accurately and cost-efficiently. To meet these goals we developed the Synthetic Plasma Pool Cohort Correction, the ‘SPOC correction’ approach, based on the use of an OLINK-composed synthetic plasma sample. The method can easily be implemented in a federated data-sharing context which is illustrated on a sepsis use case.

12 June 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DHDries Heylen
Dries Heylen
CCCharlotte De Clerck
Charlotte De Clerck
MPMurih Pusparum
Murih Pusparum
ARAlejandro Correa Rojo
Alejandro Correa Rojo
RHRosette Van Den Heuvel
Rosette Van Den Heuvel
NLNathalie Lambrechts
Nathalie Lambrechts
Objectives: The I AM Frontier cohort was set up to support proof-of-concepts aimed at personalized prevention and health promotion. The study was designed to identify patterns, markers and processes involved in the spectrum between health and early disease onset, with the aim of generating actionable insights in a clinical setting. Study design: A prospective cohort study. The study was approved by the ethics committee of the Antwerp University Hospital (RegN°: B300201938600). Methods: Data collection in the I AM Frontier study spanned 12 months as a longitudinal small-scale cohort study (n = 30) conducted in the Antwerp region of Flanders, Belgium. Participants were employees of the company hosting the study, who did not have a clinical diagnosis and were between 45–60 years old. Results: Even though no severe health problems were recorded at baseline, participants reported several physical complaints. There was a clear difference in longitudinal variation between clinical and research grade omics types, which might have affected their respective ability to detect intermediate molecular changes that were be linked to phenotype changes. Conclusion: By integrating findings from the IAF cohort into a large-scale cohort on personalized prevention, and incorporating new technologies for microsample data collection and participant engagement, we can develop more precise and individualized health recommendations.

14 December 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DHDries Heylen
Dries Heylen
JPJannes Peeters
Jannes Peeters
JAJan Aerts
Jan Aerts
GEGökhan Ertaylan
Gökhan Ertaylan
JHJef Hooyberghs
Jef Hooyberghs
One of the challenges in multi-omics data analysis for precision medicine is the efficient exploration of undiscovered molecular interactions in disease processes. We present BioMOBS, a workflow consisting of two data visualization tools integrated with an open-source molecular information database to perform clinically relevant analyses (https://github.com/driesheylen123/BioMOBS). We performed exploratory pathway analysis with BioMOBS and demonstrate its ability to generate relevant molecular hypotheses, by reproducing recent findings in type 2 diabetes UK biobank data. The central visualisation tool, where data-driven and literature-based findings can be integrated, is available within the github link as well. BioMOBS is a workflow that leverages information from multiple data-driven interactive analyses and visually integrates it with established pathway knowledge. The demonstrated use cases place trust in the usage of BioMOBS as a procedure to offer clinically relevant insights in disease pathway analyses on various types of omics data.

17 May 2024 in medRxiv
Verified
Preprint
Open access
PDF file
DHDries Heylen
Dries Heylen
CCC. De Clerck
C. De Clerck
MPM. Pusparum
M. Pusparum
ARA. Correa Rojo
A. Correa Rojo
RHRosette Van Den Heuvel
Rosette Van Den Heuvel
NLNathalie Lambrechts
Nathalie Lambrechts
Purpose The I AM Frontier cohort was set up to support proof-of-concepts aimed at precision health and more specifically personalized prevention and health promotion. The study was designed to identify patterns, markers and processes, that play a role in the spectrum between health and early onset of disease and may provide actionable information in a clinical setting, taking into account all ethical, legal and logistical aspects. Participants The first phase of the I AM Frontier study ran for 12 months as a longitudinal small-scale cohort study (n=30) in the Antwerp region of Flanders, Belgium. Participants were employees of the company hosting the study, they did not have a clinical diagnosis and were between 45-60 years old. Findings to date Even though no severe health problems are recorded at baseline, participants did report several physical complaints. There is a clear difference in longitudinal variation between clinical and research grade omics types, which might affect their respective ability to detect intermediate molecular changes that can be linked to phenotype changes. Future plans This cohort is being used to further support the design and implementation of a larger population health cohort with selected modalities for investigating feasibility of personalized prevention in real life setting. Future research will build on this longitudinal dataset to derive healthy yearly fluctuations (or normal ranges) at individual level for predicting early on-set deviations Registration The study was approved by the ethical committee of the Antwerp University Hospital (RegN°:B300201837314). Strengths and limitations summary The I AM Frontier proof-of-concept (POC) cohort study is unique in that it collected an extensive range of samples, with high longitudinal frequency, of healthy individuals for 12 months. The implemented sampling technologies (for clinical parameters, whole genome sequencing (WGS), methylation, quantitative proteomics, metabolomics, microbiome, retina scans, wearables, and standardized questionnaires on e.g. food intake and medical status in combination with genome sequencing at the start of the study) were selected to maximize overlap with large cross-sectional studies and biobanks such as e.g. UK biobank to allow comparison of phenotypical profiles present across different studies. The highly granular (i.e. collected with high longitudinal frequency) data within this study allows us to construct dense participant profiles. Frequent longitudinal data collection of multi-omics data is emerging with new technical advancements for the in-depth analyses of molecules in small blood volumes. To allow the routine usage of such measurements in clinical practice, the temporal changes observed in this cohort can serve to evaluate the frequency and added value of such highly granular measurements. Perceptions of precision health, such as communication of clinical follow-up data, personal risks from genomics, behavioral aspects, and the ethical dilemmas that go together with all of this, are included in the scope of the cohort.

1 September 2026
Verified
Preprint
Open access
DHDries Heylen
Dries Heylen
ALAlejandro Adriaque Lozano
Alejandro Adriaque Lozano
MMMichelle Moerel
Michelle Moerel
MKMartina Kutmon
Martina Kutmon
Post-COVID is a complex, multi-system disorder with symptoms persisting for months to years. While it affects increasing numbers of individuals worldwide, no targeted treatments currently exist. To address this gap, we used pyBioDataFuse to construct a disease-specific post-COVID knowledge graph, integrating transcriptomics data from post-COVID patient muscle biopsies with data from multiple curated molecular resources. The resulting graph comprised 13,284 nodes and 54,009 edges, covering molecular interactions, gene-disease associations, and drug-target relationships. Two complementary network-based drug repurposing algorithms, DREAMwalk and PoLo, were applied to prioritize therapeutic candidates. The identified candidates span mechanistically distinct drug classes including GABAergic modulators, ion channel modulators, and BTK inhibitors. These candidates collectively reflect the multi-faceted nature of post-COVID. Several GABAergic modulators and Metformin, a metabolic agent with anti-inflammatory properties, emerged as the strongest cross-algorithm candidates, with Metformin supported by observational evidence of an association with reduced post-COVID incidence. This reproducible, open-source pipeline provides a transparent and extensible framework for network-based drug repurposing in post-COVID and other complex diseases